BioMérieux Records Q1 2026 Sales Decline Amid Weak Respiratory Season

In the first quarter of 2026, bioMérieux reported a -3.9% decline in organic sales, attributed to a mild respiratory epidemiology and an uncertain geopolitical and macroeconomic environment. This translated into a 23% drop in BIOFIRE® respiratory panels sales and an 18% decrease in instrument sales. Despite these setbacks, the company's reagents for GO•28 growth drivers saw a 6.5% increase, led by SPOTFIRE®'s 31% rise.

Looking ahead, bioMérieux adjusted its full-year guidance, with expected organic sales growth between 3% to 5%. CEBIT growth forecast has also been reduced to a range of 0% to 10%, excluding Middle East impacts. Key developments included the SPOTFIRE® mini assays launch in Europe and the acquisition of Accellix, enhancing pharmaceutical quality control capabilities.